Onset to perceived effect: None acute. This is a preventive/chronic compound — you don't feel the dose. MPOD changes are measurable at 8-12 weeks of consistent dosing; visual performance gains (contrast sensitivity, glare recovery, photostress recovery) emerge between 3 and 6 months.

What users report after 3+ months on AREDS2 dose:

• Reduced eye strain during long screen sessions
• Faster recovery after walking from dim indoor environment into bright sunlight
• Reduced headlight glare during night driving
• Reduced "screen burn" sensation after 8+ hour computing days
• Subjectively crisper contrast under bright office fluorescents
• Some users with prior digital eye strain report reduced dry-eye burn

What users do NOT report:

• Acute cognitive boost
• Energy or focus changes hour-to-hour
• Sleep improvement at typical doses (Stringham's signal was in heavy screen users; less dose-response data in normal-screen users)

Honest variability: A substantial fraction of supplementation effects are subclinically perceived — MPOD goes up, contrast sensitivity improves measurably on Pelli-Robson charts, but the user can't feel the difference. This is why lutein doesn't drive strong subjective stack reports — it's working but quietly. Best perceived effect: heavy-screen users with pre-existing eye strain see meaningful symptom relief; people with already-good visual function notice less.

• No tolerance. Lutein is not a receptor-mediated drug; it's a structural pigment that physically accumulates in target tissues. There is no analog of catecholamine depletion or receptor downregulation.
• No cycling. Continuous chronic intake is the protocol — both for AREDS2-style AMD-progression benefit and for visual-performance maintenance.
• Discontinuation kinetics: MPOD declines slowly over months after stopping; full return to dietary-input baseline takes ~6-12 months. No rebound effect.
• Practical implication: Lutein is a "set and forget" supplement. Buy a 6-month supply, take it consistently, and reassess based on dietary patterns and budget — not based on "feel."

Synergistic with

• zeaxanthin (mandatory pairing): AREDS2 protocol = 10 mg L + 2 mg Z (5:1 ratio, the natural ratio in retinal macular pigment). Lutein dominates parafoveal macula; zeaxanthin dominates fovea. Together they cover the full spatial distribution of macular pigment. Never supplement lutein alone clinically.
• meso-zeaxanthin: Some formulations add 0.5-2 mg meso-zeaxanthin. Meso-zeaxanthin is endogenously formed in the retina from lutein via RPE65 isomerization, but supplemental meso-Z may speed time-to-plateau. Optional add; not in the AREDS2 protocol.
• omega-3 (especially DHA): DHA is the major lipid in photoreceptor outer-segment membranes. Lutein partitions into these same membranes. AREDS2 sub-analyses showed an interaction (L+Z benefit was strongest when combined with EPA+DHA in baseline-low-fish-eaters). Dylan's V4 stack already includes omega-3 — synergistic.
• vitamin E (α-tocopherol): Regenerates oxidized carotenoid radicals and shares lipoprotein transport. Mild kinetic synergy.
• vitamin C: Recycles oxidized vitamin E, indirectly supporting the carotenoid recycling pathway. Already V4-locked.
• zinc: Original AREDS formula component. RPE concentrates zinc and uses it as antioxidant cofactor. Modest direct synergy with L+Z protection of retinal tissue.
• astaxanthin: Different carotenoid class (ketocarotenoid) — partitions into both leaflets of the bilayer where lutein has a surface preference. Some evidence (Senju 2023) for combined eye-strain and eye-hand coordination benefit. Reasonable optional stack for screen-heavy users.
• dietary fat (5+ g per dose): Tripled to quadrupled absorption. Not a "stack" per se but co-ingestion with fat is non-negotiable for full bioavailability.

Avoid stacking with

• beta-carotene at high dose (>10-15 mg): Competes at intestinal SR-BI/CD36 carotenoid uptake transporters. High-dose beta-carotene can reduce serum lutein by 30-40%. Plus the former-smoker lung cancer signal. Dietary beta-carotene from food is fine; supplemental high-dose beta-carotene defeats lutein supplementation.
• Cholestyramine, orlistat, plant sterol esters: Bile-acid sequestrants and fat-blockers reduce carotenoid absorption.
• Fat-free or very-low-fat meal: Functional zero absorption.

Neutral / safe co-administration

• All of Dylan's V4 supplements (Mg, NAC, citicoline, PS, DHA, curcumin, rhodiola, theanine, glycine, D3/K2, beta-alanine, vitamin C, zinc) — neutral or modestly synergistic.
• Creatine — neutral.
• Caffeine — neutral.
• Modafinil — neutral. No CYP interaction.
• Standard SSRIs, statins, blood pressure medications — neutral.
• Peptides (BPC-157, TB-500, Semax, Selank) — neutral.

Lutein's metabolic profile:

• Absorbed via intestinal SR-BI and CD36 carotenoid uptake transporters (shared with other carotenoids — competition site).
• Transported on chylomicrons → liver → repackaged onto LDL/HDL for systemic distribution.
• Not metabolized by CYP450 system at clinically relevant doses (free lutein is not a CYP substrate).
• Eliminated primarily via biliary excretion of unchanged compound; minor urinary metabolites.

Clinically meaningful interactions: essentially none at supplementation doses.

1. Beta-carotene (high-dose) — competition at intestinal uptake. Reduce serum lutein 30-40% if co-supplemented at >20 mg beta-carotene/day. Use serum or MPOD monitoring if both are supplemented.

2. Statins — no significant interaction. Some early concern about lipoprotein-bound carotenoid transport on LDL-lowering therapy; not borne out clinically.

3. Cholestyramine, orlistat — reduced absorption. Take lutein at least 4 hours apart from these agents.

4. Plant sterol esters (e.g., Benecol margarines) — reduced absorption (~15-20% reduction). Cosmetic; not clinically meaningful.

5. No warfarin interaction. Lutein is not vitamin-K-active.

6. No hormonal contraceptive interaction. Lutein is not a CYP3A4 inducer.

7. No psychiatric medication interaction. Lutein has no monoaminergic activity.

Lutein pharmacokinetics show substantial inter-individual variability (~3-5× range in serum response to fixed dose). Three identified genetic modulators:

BCMO1 (β-carotene 15,15'-monooxygenase) polymorphisms: ~40% of population carries low-activity variants. Does not directly affect lutein metabolism (lutein is not BCMO1 substrate; only provitamin-A carotenoids are), but BCMO1 status indirectly correlates with overall carotenoid status because low-BCMO1 individuals accumulate beta-carotene without cleavage, which can suppress lutein uptake via competitive transport effects.

SR-BI (scavenger receptor class B type 1) polymorphisms (SCARB1 gene): Modulate intestinal carotenoid uptake efficiency. High-uptake variants increase serum lutein response to fixed oral dose by ~30-50%. Some 23andMe SNPs (rs5888, rs838880) tag SCARB1; can be inferred from raw data via Promethease.

APOE genotype: APOE4 carriers (~25% of population) have differential carotenoid lipoprotein transport. APOE4 carriers may benefit MORE from lutein supplementation for cognitive endpoints because they have higher baseline neural oxidative stress and lower endogenous carotenoid neural delivery. Modest signal; not dose-modifying.

Practical implication for Dylan: Once 23andMe results land in June 2026, SCARB1 SNPs are worth flagging — high-uptake variant means modest dose may suffice; low-uptake variant suggests sticking with 10 mg L + 2 mg Z (not lowering further). APOE4 status would shift verdict marginally toward STRONG-CANDIDATE if present.

Recommendation for Dylan: Default to dietary lutein (eggs + leafy greens) — already in budget, already in routine. Add NOW or Doctor's Best 10/2 mg supplement during cutting phases or training camps when leafy-green consistency drops, or if eye strain emerges from prolonged screen work during the wiki project. No need for premium formulations or AREDS2 full-replica products (he doesn't have AMD risk factors).

Form notes:

• Free-form lutein (FloraGLO): Gold standard. Higher bioavailability per labeled mg. Most clinical evidence is on this form.
• Lutein esters (Xangold): Cheaper; requires intestinal hydrolysis to free form. ~15-20% lower bioavailability per labeled mg.
• Avoid: Crude marigold extracts without standardization, generic "vision support" blends with sub-therapeutic L+Z and large doses of fillers/proprietary blends.

Baseline (before starting, optional)

• Serum lutein + zeaxanthin (specialty lab; not standard panel). Useful only if comparing to post-supplementation values. ~$50-80 add-on.
• MPOD via heterochromatic flicker photometry (specialty ophthalmology / optometry office; not all offer). Quantifies macular pigment density. Most rigorous endpoint.
• Dietary lutein intake estimate — 3-day food diary. If you eat 2+ cups leafy greens + 2+ egg yolks daily, you're already at AREDS2-equivalent intake and supplementation is low-value.
• Subjective symptoms VAS — eye strain (0-10), photostress recovery time after walking into bright sun, glare difficulty during night driving, headache frequency. Useful for personal n=1 comparison.
• Visual acuity + contrast sensitivity — annual eye exam baseline (Pelli-Robson chart for contrast sensitivity if testable).

During use (if supplementing)

• Subjective eye strain VAS at month 3 and month 6 — primary outcome for screen-heavy users.
• Photostress recovery time at month 3 and 6 — secondary outcome; phone stopwatch + flashlight test (informal).
• Visible carotenodermia check at month 6 — only if dose >20 mg/day chronic; not relevant at AREDS2 dose.

Post-supplementation (if cycling off)

• Subjective symptoms after 3 months off — calibrates real benefit vs placebo/expectancy.
• MPOD persistence — declines slowly; reading at 6 months post-stop reveals individual washout kinetics.

Lifetime tracking (AMD-relevant only)

• Annual dilated eye exam (standard ophthalmology) — required if AMD family history; gold standard for early drusen detection. Lutein supplementation is supportive, not a substitute.